CRK7 modifies the MAPK pathway and influences the response to endocrine therapy

Carcinogenesis

Volumn 30, Issue 10, 2009, Pages 1696-1701

  Iorns, Elizabeth ^a,b   Martens de Kemp, Sanne R ^a,c   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; CYCLIN DEPENDENT KINASE 2 RELATED KINASE 7; ESTROGEN; FULVESTRANT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; ESTROGENS; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; TAMOXIFEN;

EID: 70349986397     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp187     Document Type: Article

References (21)

1. EBCTCG. (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 351, 1451-1467.
2. Cariou,S. et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl Acad. Sci. USA, 97, 9042-9046.
3. Musgrove,E.A. et al. (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl Acad. Sci. USA, 91, 8022-8026.
4. Jordan,V.C. (1995) Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer" - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat., 36, 267-285.
5. Ring,A. et al. (2004) Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer, 11, 643-658.
6. Iorns,E. et al. (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell, 13, 91-104.
7. Ko,T.K. et al. (2001) CrkRS: A novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J. Cell Sci., 114, 2591-2603.
8. Chen,H.H. et al. (2006) Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. iMol. Cell. Biol., 26, 2736-2745.
9. Echeverri,C.J. et al. (2006) Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods, 3 777-779.
10. Jones,S.E. (2002) A new estrogen receptor antagonist - an overview of available data. Breast Cancer Res. Treat., 75 (suppl. 1), S19-S21; (discussion S33-S35).
11. Santen,R.J. et al. (2005) Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J. Steroid Biochem. Mol. Biol., 95, 155-165.
12. Wilcken,N.R. et al. (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res., 3, 849-854.
13. Sherr,C.J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
14. Altucci,L. et al. (1996) 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene, 12, 2315-2324.
15. Shou,J. et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst., 96, 926-935.
16. Jakowlew,S.B. et al. (1984) Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res., 12, 2861-2878.
17. Oh,A.S. et al. (2001) Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol. Endocrinol., 15 1344-1359.
18. Lavoie,J.N. et al. (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem., 271, 20608-20616.
19. Johnston,S.R. et al. (2003) Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res., 9, 524S-532S.
20. Bedard,P.L. et al. (2008) Overcoming endocrine resistance in breast cancer: Are signal transduction inhibitors the answer? Breast Cancer Res. Treat., 108, 307-317.
21. Kasten,M. et al. (2001) Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene, 20, 1832-1838.